Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

LEGN

NASDAQ

Legend Biotech (LEGN)

19 USD +2.43% vs prior close
Legend Biotech Corporation price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Revenue from contracts with customers, year to Dec 2025
1.0B USD
EPS, diluted, year to Dec 2025
−0.81 USD
52-week range
16.65 USD – 42 USD
Avg volume
584.2K

as of Aug 3, 2026

Have Legend Biotech (LEGN) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Legend Biotech insiders reported 2 open-market sales and 3 purchases (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest reported trade 17 Nov 2026

3buys
2sells
$38Knet bought
8other filings
Have Legend Biotech (LEGN) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
17 Nov 2026Zhang IngridChief Executive OfficerBuy20,000163K USD
13 Nov 2026Salovey PeterDirectorBuy10,00090K USD
12 Nov 2026Salovey PeterDirectorBuy10,00094K USD
29 Sep 2026Sanders Corazon (Corsee) D.DirectorSell27,370259K USD
21 Sep 2026Santos Carlos EChief Financial OfficerSell5,43050K USD
Bought3 open-market purchases40,000$346K
Sold2 open-market sales32,800$309K
8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Legend Biotech (LEGN) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
24 Sep 2026Casey Patrick JohnDirectorAward20,986
24 Sep 2026Heyman Tomas J.DirectorAward20,986
24 Sep 2026Ji Darren XiaohuiDirectorAward28,330
24 Sep 2026Sanders Corazon (Corsee) D.DirectorAward20,986
24 Sep 2026Salovey PeterDirectorAward28,330
24 Sep 2026Mao LiDirectorAward20,986
21 Sep 2026Santos Carlos EChief Financial OfficerAward19,676
15 Sep 2026Zhang IngridChief Executive OfficerAward1,131,860

Which funds hold Legend Biotech (LEGN)?

7 of the 45 institutional funds we track reported a Legend Biotech position for the quarter ended 30 Sep 2026 — a combined 121.4M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Legend Biotech (LEGN)?
FundPositionSharesValueShares q/q
Point72 Asset ManagementTrimmed1,604,46631.9M USD−47.8%
Two Sigma InvestmentsAdded1,522,16330.3M USD+828.7%
Renaissance TechnologiesHeld (±25%)1,227,30024.4M USD+22.7%
Balyasny Asset ManagementAdded1,178,04223.4M USD+458.3%
Citadel AdvisorsAdded493,3109.8M USD+1,344.9%
Tudor Investment CorpAdded69,9421.4M USD+140.6%
Marshall WaceTrimmed10,434208K USD−94.8%

What has been filed or recorded for Legend Biotech (LEGN)?

The filings we hold for Legend Biotech, newest first: 6 fails-to-deliver days and 5 reported financial figures, the latest dated 30 Oct 2026.

What has been filed or recorded for Legend Biotech (LEGN)?
And
30 Oct 2026Fails to deliverShares failed to deliver340 shares8K USD notional · <0.001% of shares out
29 Oct 2026Fails to deliverShares failed to deliver47,408 shares1.1M USD notional · 0.013% of shares out
22 Oct 2026Fails to deliverShares failed to deliver44,445 shares828K USD notional · 0.012% of shares out
16 Oct 2026Fails to deliverShares failed to deliver33 shares653 USD notional · <0.001% of shares out
15 Oct 2026Fails to deliverShares failed to deliver66,772 shares1.3M USD notional · 0.018% of shares out
14 Oct 2026Fails to deliverShares failed to deliver15,625 shares279K USD notional · 0.004% of shares out
31 Dec 2025FinancialsRevenue from contracts with customers1.0B USDfiscal year
31 Dec 2025FinancialsNet income−296.8M USDfiscal year
31 Dec 2025FinancialsDiluted earnings loss per share−0.81 USDfiscal year
31 Dec 2025FinancialsTotal assets1.7B USDat period end
31 Dec 2025FinancialsEquity1.0B USDat period end

What do people ask about Legend Biotech (LEGN)?

From live data
What is Legend Biotech’s revenue?1.0B

Legend Biotech reported revenue from contracts with customers of 1.0B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Legend Biotech insiders bought or sold shares recently?2 sales

In the 90 days to 22 Nov 2026, Legend Biotech insiders reported 2 open-market sales and 3 purchases (SEC Form 4). A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Legend Biotech?7 of 45

7 of the 45 funds we track reported a Legend Biotech position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Point72 Asset Management, Two Sigma Investments and Renaissance Technologies. See Funds

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 31 Dec 2025